Alxerion Biotech LLC is building a biobank of exosomes from diverse species as a comprehensive source for therapeutics discovery. Its initial focus is on cancer.
The company aims to collect and screen 350,000 samples from 30,000 species encompassing a wide range of symbiotic and competing life forms. Exosomes from natural competitors could contain agents with antibiotic, antifungal, antiproliferative or anti-inflammatory properties.
“The pharmaceutical industry strayed away from new